论文部分内容阅读
目的:研究并探讨辛伐他汀联合参附注射液治疗合并糖尿病的急性心肌梗死患者心力衰竭的临床疗效。方法:于2012年6月—2014年2月,选取该阶段内本院收治的88例合并糖尿病的急性心肌梗死患者作为此次研究的对象,采取数字随机表法将患者随机分为对比组和实验组,每组44例。对比组采取常规治疗,实验组在常规治疗的基础上加用参附注射液。比较两组患者的血脂水平、左心功能、炎性标志物水平、药物不良反应、远期生存率。结果:治疗后,实验组的总胆固醇、甘油三酯以及低密度脂蛋白胆固醇均较对比组更低(P<0.05),实验组的BNP以及超敏C反应蛋白均较对比组明显更低(P<0.05)。与治疗前相比,治疗后两组患者的左室间隔厚度、左心后壁厚度、左室舒张末期内径以及左室射血分数均明显改善(P<0.05),且两组之间比较,差异均具有统计学意义(P<0.05)。两组患者均未出现明显的不良反应。随访2年发现,实验组的2年生存率为95.45%,较对比组更高。结论:在合并糖尿病且出现心力衰竭的急性心肌梗死患者治疗过程中,给予患者辛伐他汀联合参附注射液治疗,可有效降低患者机体内的血脂水平以及炎性反应,还可有效改善患者的左心功能,提高远期生存率,且安全可靠。
Objective: To study and investigate the clinical efficacy of simvastatin combined with Shenfu injection in the treatment of heart failure in patients with acute myocardial infarction complicated with diabetes mellitus. Methods: From June 2012 to February 2014, 88 patients with acute myocardial infarction with diabetes mellitus admitted to our hospital during this period were selected as the object of this study. The patients were randomly divided into control group and control group Experimental group, 44 cases in each group. The control group to take conventional treatment, the experimental group on the basis of conventional treatment with Shenfu injection. Blood lipid levels, left ventricular function, levels of inflammatory markers, adverse drug reactions and long-term survival were compared between the two groups. Results: After treatment, the levels of total cholesterol, triglyceride and low density lipoprotein cholesterol in the experimental group were lower than those in the control group (P <0.05). The levels of BNP and hypersensitive C-reactive protein in the experimental group were significantly lower than those in the control group P <0.05). Compared with those before treatment, left ventricular septal thickness, left ventricular posterior wall thickness, left ventricular end-diastolic diameter, and left ventricular ejection fraction were significantly improved in both groups after treatment (P <0.05) The differences were statistically significant (P <0.05). No significant adverse reactions occurred in both groups. Follow-up 2 years found that the 2-year survival rate of the experimental group was 95.45%, higher than the control group. Conclusion: Simvastatin combined with Shenfu injection in patients with acute myocardial infarction complicated with diabetes and heart failure can effectively reduce the level of lipids and inflammatory reaction in patients with acute myocardial infarction, and can effectively improve the patients’ Left heart function, improve long-term survival, and safe and reliable.